Tumor-naive multimodal profiling of circulating tumor DNA to detect minimal residual disease in solid tumors.

ABSTRACT:

Background

Circulating tumor DNA (ctDNA) analysis that is tumor-informed and personalized requires high-quality tissue specimens, which are unavailable in certain clinical contexts and pathology practice in Southeast Asia.

Objectives

We aimed to develop and clinically validate an alternative tumor-naïve ctDNA assay.

Design

A retrospective observational study.

Methods

Our tumor-naïve multimodal profiling integrated mutation detection, using both amplicon and hybridization sequencing, with analysis of copy number alteration (CNA) and fragmentomics of cfDNA. We analyzed blood samples of 948 cancer patients and 566 non-cancer donors enrolled in previous studies to evaluate the analytical performance of ctDNA detection. Clinical performance was assessed using post-s

SUBMITTER: Nguyen T 

PROVIDER: S-EPMC12627382 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature